Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Avelumab plus cetuximab rechallenge versus cetuximab alone in pre-treated RAS/BRAF wild-type metastatic colorectal cancer
2021-004593-56Phase 2Active
- Sponsor
- Gruppo Oncologico dell'Italia Meridionale
- Start
- Mar 2022
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised trial in colorectal cancer (CRC) and metastatic colorectal adenocarcinoma (mCRC) comparing Avelumab plus cetuximab with Cetuximab alone (2 arms). Primary endpoint: Overall survival. Started Mar 2022; status: active.
02
Drugs
cetuximabavelumab
03
Conditions
colorectal cancer (CRC)metastatic colorectal adenocarcinoma (mCRC)
Beyond the preview
Go deeper on 2021-004593-56.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-004593-56.